Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Mouth and Tooth Diseases

Digestive System Diseases

Rare Diseases

Uterine Cervical Neoplasms

Recurrence

Breast Neoplasms

Head and Neck Neoplasms

Sarcoma

Neoplasm Metastasis

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Lymphadenopathy

Pelvic Neoplasms

Mouth Neoplasms

Anus Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplastic Processes

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Mouth Diseases

Stomatognathic Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Soft Tissue Sarcoma

Oral Cancer

Anal Cancer

Lip and Oral Cavity Cancer

Hematinics

All Drugs and Chemicals

Antineoplastic Agents

Dermatologic Agents

Liver Extracts

Talaporfin

Photosensitizing Agents

LS 11(Taporfin Sodium)

Lumaflex Light Delivery Catheter

Jay Winship, MD

This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis. The treatment is limited to patients that have failed to respond to currently approved methods of treatment. The study involves a single, intravenous administration of an investigational drug, LS11 (previously studied in approximately 80 cancer patients) and the placement of a novel, flexible light delivery catheter inside the tumor by a minor surgical procedure. The activation of LS11 by the light delivery catheter over a period of 1-24 hrs may result in destruction of tumor tissue.

In this Phase I photodynamic therapy study, patients will undergo a standard CT scan to determine the suitability of the treatment. In those patients that qualify the entry criteria, a light delivery catheter will be directly inserted in the tumor through a minor surgical procedure. The patients will then be injected with the photosensitive drug, LS11. One hour following the drug injection, light energy will be delivered from the light delivery catheter for a period of 1-24 hours. The duration of the light treatment for a given patient may be based on various factors including when a given patient enters the study. Following the delivery of light energy, the light delivery catheter will be removed from the tumor. The insertion and removal of the catheter will be carried out under the guidance of CT scan. The patients will be asked to take precautions from external light exposure for a period of time. The patients will undergo CT scan and other tests on days 7, 14 and 42 to evaluate safety of the treatment, tumor cell death and treatment response. Blood samples will be taken at different time points to examine the clearance of the drug from the body.

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

A Multicenter Phase I Safety and Tolerability Study of the Oncolux System for Intratumoral Delivery of Non-Coherent Light for the Photoactivation of LS 11 in Patients With Refractory Solid Tumors

Light Sciences LLC

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors	NCT00028405	Liver Metastasi... Pelvic Cancer Head and Neck C... Sarcoma Rectal Cancer Breast Cancer Colorectal Canc... Mouth Cancer	LS 11(Taporfin ... Lumaflex Light ...	18 Years -	Light Sciences LLC
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors	NCT00028405	Liver Metastasi... Pelvic Cancer Head and Neck C... Sarcoma Rectal Cancer Breast Cancer Colorectal Canc... Mouth Cancer	LS 11(Taporfin ... Lumaflex Light ...	18 Years -	Light Sciences LLC

Spots Global Cancer Trial Database for lumaflex light delivery catheter